Stockreport

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Immix Biopharma, Inc.  (IMMX) 
PDF – Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH [Read more]